Hypercholesterolemia Treatment Pipeline Shows Strong Momentum as 25+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "Hypercholesterolemia Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Hypercholesterolemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Hypercholesterolemia Research. Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hypercholesterolemia Pipeline Report
• On December 11, 2025- Kowa Company, Ltd. initiated a phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Statin Intolerant Hypercholesterolemia
• In November 2025, AstraZeneca announced a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.
• In November 2025, Merck Sharp & Dohme LLC conducted a phase 3 study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.
• DelveInsight's Hypercholesterolemia pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Hypercholesterolemia treatment.
• The leading Hypercholesterolemia Companies such as Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.
• Promising Hypercholesterolemia Pipeline Therapies such as Gemcabene, Rosuvastatin calcium, KJX839, statins, ezetimibe, MK-0524A, ER Niacin and others.

Stay informed about the cutting-edge advancements in Hypercholesterolemia treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Hypercholesterolemia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hypercholesterolemia Pipeline Report also highlights the unmet needs with respect to the Hypercholesterolemia.

Hypercholesterolemia Overview
Hypercholesterolemia is a specific type of hyperlipidemia. Hypercholesterolemia can be defined as a LDL-cholesterol greater than 190 mg/dL, greater than 160 mg/dL with one major risk factor, or greater than 130 mg/dL with two cardiovascular risk factors. Hypercholesterolemia can be inherited, but it's often the result of unhealthy lifestyle choices, which make it preventable and treatable. A healthy diet, regular exercise and sometimes medication can help reduce high cholesterol. Increases the risk of heart disease.

Hypercholesterolemia Emerging Drugs Profile
• MK-0616: Merck Sharp & Dohme LLC
MK-0616 is an investigational, potentially first oral PCSK9 inhibitor designed to lower low density lipoprotein (LDL) cholesterol. Discovered and developed by Merck, MK-0616 is a macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors. MK-0616 is being developed under an agreement with UCB Pharmaceuticals. Results from the Phase IIb clinical trial evaluating MK-0616 showed that MK-0616 was generally well-tolerated with no overall trends across treatment groups in discontinuation rates or adverse events at week 16. No serious adverse events that were considered by the investigator to be related to treatment with MK-0616 were reported. Currently the drug is in Phase III stage for the treatment of Hypercholesterolemia.

• ARO-ANG 3: Arrowhead Pharmaceuticals
ARO-ANG3 is an investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), a hepatocyte expressed regulator of lipid and lipoprotein metabolism with multiple potential modes of action, including inhibition of lipoprotein lipase and endothelial lipase. Given the inhibitory role of ANGPTL3 in the metabolism of various lipoproteins and triglycerides, reduced expression and reduced circulating levels of ANGPTL3 may increase clearance of LDL-cholesterol, HDL-cholesterol, and triglycerides. Currently the drug is in Phase II stage for the treatment of Hypercholesterolemia.

• VXX-401: Vaxxinity, Inc.
VXX-401 was designed using Vaxxinity's proprietary synthetic peptide vaccine platform and is being developed for the treatment of hypercholesterolemia. The platform is designed to harness the immune system to convert the body into its own natural "drug factory," stimulating the production of antibodies. VXX-401 is designed to induce robust, long-acting antibodies against PCSK9 and lower LDL cholesterol to prevent or treat coronary heart disease. Currently the drug is in Phase I stage for the treatment of Hypercholesterolemia.

Learn more about Hypercholesterolemia Drugs opportunities in our groundbreaking Hypercholesterolemia research and development projects @ https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Hypercholesterolemia Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hypercholesterolemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypercholesterolemia Treatment.
• Hypercholesterolemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypercholesterolemia market.

Hypercholesterolemia Companies
Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.

Hypercholesterolemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Hypercholesterolemia Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Hypercholesterolemia treatment by visiting our website. Stay informed about how we're transforming the future of Cardiovascular Diseases @ https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hypercholesterolemia Pipeline Report
• Coverage- Global
• Hypercholesterolemia Companies- Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.
• Hypercholesterolemia Pipeline Therapies- Gemcabene, Rosuvastatin calcium, KJX839, statins, ezetimibe, MK-0524A, ER Niacin and others.
• Hypercholesterolemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hypercholesterolemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Hypercholesterolemia Pipeline on our website @ https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Hypercholesterolemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypercholesterolemia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. MK-0616: Merck Sharp & Dohme LLC
9. Mid-Stage Products (Phase II)
10. ARO-ANG 3: Arrowhead Pharmaceuticals
11. Early Stage Products (Phase I)
12. VXX-401: Vaxxinity, Inc.
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Hypercholesterolemia Key Companies
17. Hypercholesterolemia Key Products
18. Hypercholesterolemia- Unmet Needs
19. Hypercholesterolemia- Market Drivers and Barriers
20. Hypercholesterolemia- Future Perspectives and Conclusion
21. Hypercholesterolemia Analyst Views
22. Hypercholesterolemia Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.